trending Market Intelligence /marketintelligence/en/news-insights/trending/sk43v7jTHt6hwkhA_NDZzA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Titan seeks $9M in underwritten public offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Titan seeks $9M in underwritten public offering

Titan Pharmaceuticals Inc. priced an underwritten public offering of units to raise $9 million in gross proceeds.

After the South San Francisco-based pharmaceutical company issued the pricing information, the stock tumbled 51%, closing at 18 cents on Oct. 16. The previous day's closing price was 36.75 cents.

Titan Pharmaceuticals, which develops implants for maintenance treatment of opioid addiction, is selling 40 million units in the offering at 22.5 cents apiece. Each unit in the offering consists of a common share and a class B warrant to purchase one common share. The class B warrants can be exercised within five years to purchase one common share of Titan Pharmaceuticals for 22.5 cents.

Additionally, the company has granted underwriters an option to purchase up to 6 million common shares and/or class B warrants to purchase up to 6 million common shares.

Titan Pharmaceuticals expects to close the offering on or about Oct. 18, subject to closing conditions.

Maxim Group LLC is the sole book-running manager for the offering.